We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Novel Device Reduces Blood Draw Contamination

By LabMedica International staff writers
Posted on 01 Jun 2017
A novel device can significantly reduce contamination of blood cultures, potentially reducing risky overtreatment and unnecessary use of antibiotics for many patients. More...
This approach could also substantially reduce healthcare costs.

Thousands of patients get their blood drawn every day for blood cultures in order to diagnose serious infections such as sepsis, which can be a deadly condition. A small but significant percentage of the blood cultures are contaminated, due in part to skin fragments containing bacteria that are dislodged during a blood draw.

Scientists at the University of Nebraska Medical Center conducted a prospective, controlled study with 904 patients and 1,808 blood cultures and compared the standard procedure to an initial specimen diversion device (ISDD) to determine whether blood culture contamination was reduced. The sterile blood collection system diverts and sequesters the first 1.5 to 2 mL of blood, which often carries contaminating skin cells and microbes and this part of the blood is discarded.

The team used the SteriPath initial specimen diversion device and were able to decrease the false positive rate significantly through use of this device, from 1.78% down to 0.2%, which represents an 88% reduction. Contamination rates routinely range from 0.6% to 6% in health care institutions the USA. Costs associated with blood culture contamination per patient case ranged from USD 1,000 in 1998 to USD 8,700 in 2009. A more recent study in the USA observed excess charges of USD 8,720 per contamination event.

Mark Rupp, MD, professor and lead author of the study, said, “A lot of people think this is a minor problem. However, contaminated blood cultures are a big deal. Physicians can be led astray and patients may be harmed by additional tests and unnecessary antimicrobial therapy. What is important about this device is it can greatly limit the blood culture from being contaminated, so physicians are rarely fooled by false-positive results. It gives clinicians confidence that results are accurate.” The study was published on in the journal Clinical Infectious Diseases.


Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
8-Channel Pipette
SAPPHIRE 20–300 µL
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The Monarch Mag Cell-free DNA (cfDNA) Extraction Kit provides isolation of low-abundance cfDNA from a range of biofluids (Photo courtesy of New England Biolabs)

New Extraction Kit Enables Consistent, Scalable cfDNA Isolation from Multiple Biofluids

Circulating cell-free DNA (cfDNA) found in plasma, serum, urine, and cerebrospinal fluid is typically present at low concentrations and is often highly fragmented, making efficient recovery challenging... Read more

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Pathology

view channel
Image: The innovative classifier can guide treatment for PDAC and other immunotherapy-resistant cancers (Photo courtesy of Adobe Stock))

Single Sample Classifier Predicts Cancer-Associated Fibroblast Subtypes in Patient Samples

Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, in part because of its dense tumor microenvironment that influences how tumors grow and respond to treatment.... Read more

Industry

view channel
Image: QuidelOrtho has entered into a strategic supply agreement with Lifotronic to expand its global immunoassay portfolio (Photo courtesy of QuidelOrtho)

QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio

QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.